search
Back to results

Point of Care RandOmisation Systems for Performing Embedded Comparative Effectiveness Trials Of Routine Treatments (PROSPECTOR)

Primary Purpose

Atrial Fibrillation New Onset, Magnesium Deficiency

Status
Recruiting
Phase
Phase 4
Locations
United Kingdom
Study Type
Interventional
Intervention
Electronic Point of Care Randomisation tool
Magnesium
Sponsored by
University College, London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Atrial Fibrillation New Onset focused on measuring Electronic Health Record Trials, Point of Care Randomisation, Comparative Effectiveness Research, Learning Health Systems, Feasibility Studies

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients:

  1. Age 18 years or over.
  2. Undergoing elective surgery of complexity sufficient to warrant postoperative critical care admission (major/complex major surgery)
  3. Must be able to give written informed consent to participate

Clinicians:

1. Must be regularly involved in the care of postoperative patients in critical care.

Exclusion Criteria:

  1. Active treatment for bronchospasm preceding deployment of the electronic prompt, defined as patient receiving bronchodilator therapy or Magnesium infusion.
  2. Any documented allergy or intolerance to any preparation of supplemental Magnesium.
  3. Serum Magnesium result > 1.5 or < 0.5 mmol/L on blood tests obtained during critical care admission .
  4. Pregnancy
  5. Atrial Fibrillation on initial arrival to critical care.

Sites / Locations

  • University College London Hospitals NHS TrustRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Nudge Prompt, Liberal Magnesium Strategy

Nudge Prompt, Restrictive Magnesium Strategy

Preference Prompt, Liberal Magnesium Strategy

Preference Prompt, Restrictive Magnesium Strategy

Arm Description

This group will be randomised to receive the Nudge design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a liberal magnesium supplementation strategy.

This group will be randomised to receive the Nudge design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a restrictive magnesium supplementation strategy.

This group will be randomised to receive the Preference design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a liberal magnesium supplementation strategy.

This group will be randomised to receive the Preference design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a restrictive magnesium supplementation strategy.

Outcomes

Primary Outcome Measures

Effectiveness of Electronic Point of Care Randomisation Prompts
The proportion of each design which result in compliance with the randomised allocation by the clinician. We define compliance with the prompt as 1) the appropriate administration of supplemental magnesium, following receiving the electronic prompt, where the measured serum magnesium is less than the randomised threshold OR; 2) the appropriate withholding of supplemental magnesium following prompt deployment, where the measured serum magnesium is greater than the randomised threshold.

Secondary Outcome Measures

Acceptability to critical care clinicians of using the Electronic Point of Care Randomisation prompts assessed by semi-structured interviews
The acceptability of using electronic point of care randomisation prompts, for the investigation of routine comparative effectiveness research questions like the study example will be assessed using a program of semi-structured interviews. These interviews will be delivered to critical care clinicians who may interact with the prompts. Interview data will be evaluated using a thematic analysis approach to derive an assessment of overall acceptability.
Clinician preferences for type of Electronic Point of Care Randomisation Prompt design assessed by semi-structured interviews
Critical care clinicians will be invited to express a preference for the design of electronic randomisation prompt having been introduced to both designs. This will be evaluated using a programme of semi-structured interviews which will include simulations of both prompt designs to aid recall. Preference will be asked directly and response displayed as proportion of clinicians preferring each design (Nudge or Preference).
Acceptability to patients of using either a Pre-Emptive or Opt-Out model to obtain informed consent for the conduct of Comparative Effectiveness Research, assessed by semi-structured interview.
Patients will be invited to undertake a semi-structured interview designed to ascertain their thoughts and opinions on each type of consent model. In addition, the interview will invite patients to consider different hypothetical research questions and how acceptable they feel each method of obtaining consent is for each. Interviews will be evaluated using a thematic analysis approach and examples supporting patient viewpoints presented in the results.

Full Information

First Posted
November 8, 2021
Last Updated
October 31, 2022
Sponsor
University College, London
Collaborators
University College London Hospitals
search

1. Study Identification

Unique Protocol Identification Number
NCT05149820
Brief Title
Point of Care RandOmisation Systems for Performing Embedded Comparative Effectiveness Trials Of Routine Treatments
Acronym
PROSPECTOR
Official Title
A Single-Centre Feasibility Study of PROSPECTOR - Point of Care RandOmisation Systems for Performing Embedded Comparative Effectiveness Trials Of Routine Treatments in Critical Care
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 22, 2022 (Actual)
Primary Completion Date
February 2023 (Anticipated)
Study Completion Date
August 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University College, London
Collaborators
University College London Hospitals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Every day, doctors and nurses make hundreds of decisions about treatments - like when to start or stop them, or how frequently to give them. Ideally, decisions are based on gold standard evidence from Randomised Controlled Trials (RCTs). Unfortunately, for many treatments little or no evidence exists and clinicians must use knowledge and experience to decide what is best. As clinicians are all different, this leads to random variation in how treatments are given to patients. For example, magnesium is routinely given in intensive care to prevent abnormal heart rhythms. There is little evidence supporting this, and clinicians vary in how they administer magnesium. Traditional RCTs might be used to examine whether more magnesium is better than less magnesium, but this method is inefficient and expensive for investigating multiple comparative treatment questions. Clinical trials are becoming more efficient by using existing hospital computer systems to run them. However, research teams continue to perform tasks like randomisation manually. For questions like magnesium supplementation, which occur daily, this is labour intensive and infeasible. Hospital computer systems also possess mechanisms for prompting and alerting clinicians for particular decisions, reminding them of best practices, warning them of potential problems. These systems may be modified to allow clinicians to randomise patients, under specific conditions. The investigators propose to assess whether modified computer prompts can be used to highlight the magnesium supplementation decision to clinicians. These would prompt the clinician to evaluate the uncertainty around giving or withholding magnesium in that instance. If in agreement that the optimal decision is unclear, clinicians can choose to randomise the patient within a predetermined trial structure. If the clinician knows better, they may override the prompt and continue with their preference. In both cases, the system learns from the decision and the patient receives optimal care determined by their clinician.
Detailed Description
Trial Design: A single-centre, mixed methods, feasibility study, embedded within the Electronic Health Record System (EHRS). The study will be conducted on critical care units within University College London Hospitals NHS Trust and will involve patients undergoing elective major surgery which necessitates postoperative admission to critical care. The study will be pragmatic in nature, with minimal disruption to usual care pathways. The study will consist of three phases: Feasibility Phase - Simulation guided semi-structured interviews with clinicians. Intervention Phase - Deployment of electronic prompts to evaluate candidate clinical question. Follow Up Phase - Patient and clinician semi-structured interviews. Research Hypothesis: Electronically delivered prompts provide a feasible method of delivering point-of-care randomisation for the evaluation of routine treatments not amenable to investigation using standard clinical trial designs. Clinical Example Hypothesis: Liberal magnesium supplementation (serum concentration < 1.0 mmol/L) is superior to a restrictive supplementation strategy (serum concentration < 0.75 mmol/L) for the prevention of Atrial Fibrillation in a general critical care population. Summary of Interventions: This study will compare Nudge and Preference electronic Point-Of-Care Randomisation (ePOCR) prompts against their ability to generate compliance with randomised allocations to liberal or restrictive magnesium supplementation strategy. Following postoperative admission to the critical care unit, participants will undergo randomisation between Nudge or Preference prompts and Liberal or Restrictive magnesium supplementation strategies. After the two randomisations steps are complete, both ePOCR designs follow the same pathway for activation and deployment to the bedside nurse. Once the EHRS detects a new serum magnesium result has been received, the system will screen the participant against exclusion criteria 1-5. Each new result triggers the same screening process. If the participant is eligible to proceed, the prompt will activate and display to the bedside nurse under two conditions: Accessing of the blood test results in the EHRS. Accessing the supplemental magnesium prescription within the EHRS. Once the prompt has displayed and been acknowledged by the bedside nurse, further activation will be suppressed until a new serum magnesium result becomes available. This process will be tested in silico prior to deployment to the live EHRS and the results of testing made available as part of the study materials. Where additional supplementation is indicated by the prompt, the nurse retains control over the dose and frequency of administration, as directed by the standardised prescription. All other aspects of postoperative care remain as standard and directed by the clinical team.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation New Onset, Magnesium Deficiency
Keywords
Electronic Health Record Trials, Point of Care Randomisation, Comparative Effectiveness Research, Learning Health Systems, Feasibility Studies

7. Study Design

Primary Purpose
Other
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Two stage randomisation process with participants first randomised to receive either Nudge or Preference electronic point of care randomisation prompt design, and then randomised to receive Liberal or Restrictive magnesium supplementation strategy.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Nudge Prompt, Liberal Magnesium Strategy
Arm Type
Active Comparator
Arm Description
This group will be randomised to receive the Nudge design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a liberal magnesium supplementation strategy.
Arm Title
Nudge Prompt, Restrictive Magnesium Strategy
Arm Type
Active Comparator
Arm Description
This group will be randomised to receive the Nudge design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a restrictive magnesium supplementation strategy.
Arm Title
Preference Prompt, Liberal Magnesium Strategy
Arm Type
Active Comparator
Arm Description
This group will be randomised to receive the Preference design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a liberal magnesium supplementation strategy.
Arm Title
Preference Prompt, Restrictive Magnesium Strategy
Arm Type
Active Comparator
Arm Description
This group will be randomised to receive the Preference design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a restrictive magnesium supplementation strategy.
Intervention Type
Other
Intervention Name(s)
Electronic Point of Care Randomisation tool
Other Intervention Name(s)
Nudge Prompt Design and Preference Prompt Design
Intervention Description
Two designs of electronic point of care randomisation tool will be evaluated.
Intervention Type
Drug
Intervention Name(s)
Magnesium
Other Intervention Name(s)
Liberal and Restrictive Magnesium Supplementation Strategies
Intervention Description
Liberal Strategy: magnesium supplementation at serum level < 0.75 mmol/L Restrictive Strategy: magnesium supplementation at serum level < 1.0 mmol/L
Primary Outcome Measure Information:
Title
Effectiveness of Electronic Point of Care Randomisation Prompts
Description
The proportion of each design which result in compliance with the randomised allocation by the clinician. We define compliance with the prompt as 1) the appropriate administration of supplemental magnesium, following receiving the electronic prompt, where the measured serum magnesium is less than the randomised threshold OR; 2) the appropriate withholding of supplemental magnesium following prompt deployment, where the measured serum magnesium is greater than the randomised threshold.
Time Frame
Duration of individual participant admission to critical care, or five postoperative days, whichever is sooner
Secondary Outcome Measure Information:
Title
Acceptability to critical care clinicians of using the Electronic Point of Care Randomisation prompts assessed by semi-structured interviews
Description
The acceptability of using electronic point of care randomisation prompts, for the investigation of routine comparative effectiveness research questions like the study example will be assessed using a program of semi-structured interviews. These interviews will be delivered to critical care clinicians who may interact with the prompts. Interview data will be evaluated using a thematic analysis approach to derive an assessment of overall acceptability.
Time Frame
Throughout study duration, maximum 6 months from study start date
Title
Clinician preferences for type of Electronic Point of Care Randomisation Prompt design assessed by semi-structured interviews
Description
Critical care clinicians will be invited to express a preference for the design of electronic randomisation prompt having been introduced to both designs. This will be evaluated using a programme of semi-structured interviews which will include simulations of both prompt designs to aid recall. Preference will be asked directly and response displayed as proportion of clinicians preferring each design (Nudge or Preference).
Time Frame
Throughout study duration, maximum 6 months from study start date
Title
Acceptability to patients of using either a Pre-Emptive or Opt-Out model to obtain informed consent for the conduct of Comparative Effectiveness Research, assessed by semi-structured interview.
Description
Patients will be invited to undertake a semi-structured interview designed to ascertain their thoughts and opinions on each type of consent model. In addition, the interview will invite patients to consider different hypothetical research questions and how acceptable they feel each method of obtaining consent is for each. Interviews will be evaluated using a thematic analysis approach and examples supporting patient viewpoints presented in the results.
Time Frame
Throughout study duration, maximum 6 months from study start date

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients: Age 18 years or over. Undergoing elective surgery of complexity sufficient to warrant postoperative critical care admission (major/complex major surgery) Must be able to give written informed consent to participate Clinicians: 1. Must be regularly involved in the care of postoperative patients in critical care. Exclusion Criteria: Active treatment for bronchospasm preceding deployment of the electronic prompt, defined as patient receiving bronchodilator therapy or Magnesium infusion. Any documented allergy or intolerance to any preparation of supplemental Magnesium. Serum Magnesium result > 1.5 or < 0.5 mmol/L on blood tests obtained during critical care admission . Pregnancy Atrial Fibrillation on initial arrival to critical care.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Matthew G Wilson
Phone
02034567890
Email
matthew.wilson8@nhs.net
First Name & Middle Initial & Last Name or Official Title & Degree
Steve K Harris
Phone
02034567890
Email
S.harris8@nhs.net
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steve K Harris
Organizational Affiliation
University College London Hospitals
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Matthew G Wilson
Organizational Affiliation
University College, London
Official's Role
Principal Investigator
Facility Information:
Facility Name
University College London Hospitals NHS Trust
City
London
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthew Wilson, MBBS
Email
matthew.wilson8@nhs.net

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
36123103
Citation
Wilson MG, Asselbergs FW, Miguel R, Brealey D, Harris SK. Embedded point of care randomisation for evaluating comparative effectiveness questions: PROSPECTOR-critical care feasibility study protocol. BMJ Open. 2022 Sep 19;12(9):e059995. doi: 10.1136/bmjopen-2021-059995.
Results Reference
derived

Learn more about this trial

Point of Care RandOmisation Systems for Performing Embedded Comparative Effectiveness Trials Of Routine Treatments

We'll reach out to this number within 24 hrs